Iovance Biotherapeutics, Inc. (IOVA) Balance Sheet

NASDAQ: IOVAAssets, liabilities, debt and equity over 10 years.

IOVA balance sheet, 2025

December 31, 2025 · U.S. dollars

$913.2M assets = $214.6M liabilities + $698.6M equity

What it owns$913.2MCash & ST investments: $297.0M (32.5%)Cash & ST investments$297.0M · 33%Receivables: $82.4M (9.0%)Receivables $82.4MInventory: $51.7M (5.7%)Other current: $11.6M (1.3%)PP&E: $177.0M (19.4%)PP&E$177.0M · 19%Goodwill & intangibles: $279.3M (30.6%)Goodwill & intangibles$279.3M · 31%Other non-current: $14.1M (1.5%)=How it is financed$913.2MCurrent liabilities: $138.4M (15.2%)Current liabilities$138.4M · 15%Other LT liabilities: $76.2M (8.3%)$76.2MShareholders’ equity: $698.6M (76.5%)Shareholders’ equity$698.6M · 77%

Both columns are drawn to the same scale: what IOVA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

IOVA financial health

Current ratio3.20
Comfortable · current assets cover current liabilities 3.20×
Debt / equity0.07
Low leverage · $0.07 of debt for each $1 of equity
Equity / assets76.5%
Equity-funded · of assets funded by shareholders
Cash / debt613.0%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles30.6%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal 2025.

IOVA balance sheet trends, 2016–2025

Iovance Biotherapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$171.9M2016$913.2M2025+20.4%/yr
Total liabilities$5.0M2016$214.6M2025+52.0%/yr
Shareholders’ equity$166.9M2016$698.6M2025+17.2%/yr
Cash & short-term investments$166.5M2016$297.0M2025+6.6%/yr
Total debt$11.5M2019$48.4M2025+27.1%/yr
Net cash (debt)$295.6M2019$248.5M2025−$47.0M
Working capital$164.5M2016$304.3M2025+$139.8M
Book value per share$4.792018$1.952025−12.0%/yr
Current ratio34.1220163.202025−30.92
Debt / equity0.0420190.072025+0.03
Shares outstanding97.3M2018357.3M2025+20.4%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

IOVA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

IOVA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

IOVA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

IOVA balance sheet

Iovance Biotherapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$297.0M$323.8M$279.9M$471.8M$504.4M$629.4M$307.1M$468.5M$145.4M$166.5M
Cash & equivalents$163.1M$115.7M$114.9M$231.7M$78.2M$67.3M$14.0M$82.2M$145.4M$166.5M
Short-term investments$133.9M$208.1M$165.0M$240.1M$426.2M$562.1M$293.1M$386.4M$0$59.8M
Receivables$82.4M$69.3M$151,000$0$0$0$0$0$0$0
Inventory$51.7M$51.5M$10.4M$0$0$0$0$0$0$0
Other current assets$11.6M$12.4M$17.5M$7.3M$3.5M$6.7M$9.4M$6.9M$3.9M$3.0M
Total current assets$442.7M$457.0M$307.8M$479.1M$508.0M$636.1M$316.5M$475.4M$149.3M$169.5M
Property, plant & equipment (net)$177.0M$164.3M$176.5M$178.2M$169.9M$113.9M$19.2M$2.7M$2.5M$2.4M
Goodwill & intangible assets$279.3M$282.4M$229.3M$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$91.6M$0$0$0$0$0
Other non-current assets$14.1M$6.7M$66.7M$6.6M$7.9M$18.4M$8.9M$2.8M$3.6M$0
Total assets$913.2M$910.4M$780.4M$664.0M$777.3M$768.5M$344.7M$480.8M$155.4M$171.9M
Liabilities
Accounts payable$22.2M$27.5M$33.1M$26.6M$27.4M$13.5M$15.6M$2.7M$1.2M$863,000
Short-term debt$4.0M$12.9M$7.8M$12.6M$5.1M$6.3M$7.3M———
Deferred revenue——$1———————
Total current liabilities$138.4M$122.3M$110.3M$91.5M$89.2M$54.9M$39.1M$14.4M$9.9M$5.0M
Long-term debt$0$1.0M$1.0M$1.0M$1.0M$0$0$0$0$0
Lease obligations$48.4M$57.3M$74.9M$84.4M$70.5M$51.7M$11.5M———
Other long-term liabilities$76.2M$76.7M$84.4M$71.9M$65.5M$57.1M$6.6M$230,000$297,000$0
Total liabilities$214.6M$200.0M$195.7M$164.3M$155.7M$112.0M$45.7M$14.6M$9.9M$5.0M
Shareholders' equity
Common stock & paid-in capital$17,000$13,000$11,000$8,000$7,000$6,000$5,000$5,000$3,000$3,000
Retained earnings (deficit)−$2.78B−$2.38B−$2.01B−$1.57B−$1.17B−$830.2M−$570.6M−$372.8M−$249.2M−$157.1M
Treasury stock————————$0$0
Accumulated other comprehensive income$16.4M−$1.0M$2.5M−$902,000−$601,000$19,000$220,000−$42,000−$3.0M$29,000
Minority interest————————$0$0
Total shareholders' equity$698.6M$710.4M$584.6M$499.6M$621.7M$656.5M$299.0M$466.2M$145.5M$166.9M
Key figures
Total debt$48.4M$58.3M$75.9M$85.4M$71.5M$51.7M$11.5M———
Net cash (debt)$248.5M$265.5M$204.0M$386.4M$432.9M$577.8M$295.6M———
Working capital$304.3M$334.7M$197.5M$387.6M$418.8M$581.2M$277.4M$461.0M$139.4M$164.5M
Tangible book value$419.3M$428.0M$355.4M$499.6M$621.7M$656.5M$299.0M$466.2M$145.5M$166.9M
Book value per share$1.95$2.45$2.49$3.14$4.05$4.75$2.40$4.79——
Shares outstanding357.3M289.9M235.1M159.3M153.4M138.3M124.3M97.3M——
Current ratio3.203.742.795.245.6911.598.1033.0215.0934.12
Quick ratio2.743.212.545.165.6511.477.8632.5414.7033.51
Debt / equity0.070.080.130.170.120.080.04———
Equity / assets76.5%78.0%74.9%75.2%80.0%85.4%86.7%97.0%93.6%97.1%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 24, 2026); data from EODHD.

IOVA financial position

At the end of fiscal 2025 (December 31, 2025), Iovance Biotherapeutics had total assets of $913.2 million (up 0.3% from a year earlier), total liabilities of $214.6 million and shareholders' equity of $698.6 million. It held $297.0 million in cash and short-term investments against $48.4 million of debt, a net cash position of $248.5 million. Its current ratio was 3.20. In the latest quarter (ended June 30, 2026) total assets were $915.5 million and equity $736.0 million.

Related: IOVA income statement, IOVA cash flow statement, IOVA key metrics. See the IOVA stock overview for the latest quote and news.

IOVA balance sheet FAQ

What are Iovance Biotherapeutics's total assets?

Iovance Biotherapeutics reported total assets of $913.2 million at the end of fiscal 2025 (December 31, 2025), compared with $910.4 million a year earlier.

How much debt does Iovance Biotherapeutics have?

Iovance Biotherapeutics had $48.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.07.

How much cash does Iovance Biotherapeutics have?

Iovance Biotherapeutics held $297.0 million in cash and short-term investments at the end of fiscal 2025; with $48.4 million of debt that is net cash of $248.5 million.

What is Iovance Biotherapeutics's book value?

Iovance Biotherapeutics's shareholders' equity (book value) was $698.6 million at the end of fiscal 2025, or $1.95 per share.

What is Iovance Biotherapeutics's current ratio?

Iovance Biotherapeutics had current assets of $442.7 million and current liabilities of $138.4 million, a current ratio of 3.20 (it can cover its short-term obligations).

How much goodwill does Iovance Biotherapeutics have?

Iovance Biotherapeutics carried $279.3 million of goodwill and intangible assets, 30.6% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet